Immunic, Inc. (IMUX) Deep Dive Video

Summary

A cash-constrained, late-stage MS biotech with a dual-mechanism “neuroprotection” swing—ENSURE Phase 3 data in 2026 determines whether IMUX becomes a multibillion-dollar contender or a liquidation story.

View IMUX stock page · Read the IMUX research report

Loading the video player…